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The present dissertation discloses the doctoral work carried out during the past three years at the Italian 
Institute of Technology (IIT) and the University of Genoa. The work was focused on the functionalization 
of iron oxide nanocubes (NCs) for different biological applications. Tuning the surface features of these 
magnetic nanocubes, as well as their assembly and intrinsic chemical and physical properties, resulted in 
the development of suitable nanotools for cancer theranostic, i.e. the combination of diagnosis and cancer 
therapy.  
The first chapter deals with the synthesis of magnetic nanoclusters, referred as magnetic nanobeads 
(MNBs). Here, maghemite (γ-Fe2O3) nanocubes were tightly enwrapped into an amphiphilic polymer 
able to solubilize and stabilize them in water-based solutions. The synthetic route, reported in literature, 
was improved in order to obtain more stable polymeric shells that can be further functionalized with 
PEG-derivatized molecules. Due to the higher magnetic moment found for the MNBs, compared to that 
of single nanocubes, they were investigated for magnetic cell sorting. Therefore, a targeting feature was 
added to their surface by attaching a PEG molecule derivatized with folic acid (PEG-FA). This approach 
provides: 1) the binding of the MNBs to folate receptors overexpressed on the cell membrane of some 
cancer cells; 2) stability in complex biological media; 3) distance of the FA from the polymeric surface; 
4) degree of freedom to the bioactive folic acid. A cancer cell line having high folate receptor expression 
profile (KB cell line) was chosen as a model for testing the sorting ability of the MNBs. The results 
obtained showed a significantly higher sorting efficiency for the MNBs functionalized with PEG-FA in 
comparison to the one observed for the MNBs functionalized with a non-biologically active PEG. This 
outcome reveals the potential of PEG-FA functionalized MNBs for the isolation of relevant folate 
receptor positive cancer cells, e.g. ovarian cancer cells, from biological tissues.  
In the second chapter, the structural transformation of core-shell wuestite/maghemite (FeO/γ-Fe2O3) 
nanocubes into maghemite is reported. Here, an approach that is not often applied by material scientists 
was followed for the transformation under aqueous conditions. The non-interacting nature of core-shell 
nanocubes, due to their low magnetization, allowed for an easy and quantitative transfer in water, using 
a standard protocol for the coating with an amphiphilic polymer. Then, it was found that a mild oxidation 
process, carried out in water at 80 °C, promoted the conversion of the core-shell structure into fully 
maghemite nanocubes, enhancing their magnetic features, especially the specific absorption rate (SAR). 
Thus, the nanocubes were functionalized with PEG-FA and the annealing treatment was repeated. 
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Noteworthy, the oxidation strategy developed did not compromise the bio-functionality of the PEG-FA 
molecule. Unfortunately, the SAR values of the obtained one-phase nanocubes were found to be viscosity 
dependent, discouraging their use for magnetic hyperthermia in cellular environment. Instead, because 
annealing increased the magnetic moment of the nanocubes, they were efficiently used for the magnetic 
sorting of KB cells. The sorting efficiency found for these nanocubes was comparable to that of the 
MNBs reported in chapter 1, suggesting that a high amount of single nanocubes bound to the cell 
membrane increases the magnetic moment of the whole nanocubes-cell system. Thus, the methodology 
adopted for tuning the magnetic properties of core-shell iron oxide-based materials into one single phase 
NPs was proven appropriate for the preparation of nanocubes for magnetic driven cell sorting. 
The third chapter discusses the use of maghemite (Fe2O3) nanocubes for developing multimodal 
nanotherapeutics to treat ovarian cancer. The intriguing high heat performance of the nanocubes was 
exploited to perform magnetic hyperthermia. At the same time, the high surface area available on the 
nanocubes has been used for drug delivery and specific antibody-mediated tumor targeting towards 
ovarian cancer cells. The NCs were functionalized with both an oxaliplatin-derivatized PEG (PEG-Pt) 
and a PEG-Bis(carboxymethyl)-lysine (a nitrilotriacetic derived molecule) complex for the binding of an 
his-tag antibody fragment (scFv) specific for folate receptor α (αFR). The functionalized nanocubes were 
able to recognize their target and to be efficiently internalized by the desired cells via endocytosis 
pathway. Once inside the cells, the nanocubes delivered the Pt compound, which induced toxicity by 
intercalating the DNA. Thanks to their crystal structure and size, these nanocubes exhibited a viscosity-
independent behavior, keeping high SAR values even in highly viscous media. Indeed, once incubated 
with the cells, the nanocubes were able to heat the tumor mass up to 42 °C, promoting cell death. The 
contribution of the cytotoxicity from both Pt delivery and hyperthermia highlighted the use of these 
nanocubes for cancer multitherapy. Thus, combining targeting, drug delivery and magnetic hyperthermia, 




Introduction. Nanoparticles in medicine 
1. What is nanomedicine? 
… 
Nanomedicine concerns the use of precisely engineered materials at the nano-scale size (Figure 1.1), 
generally with at least one dimension defined in the 1-100 nm range,[1-5] to develop therapeutic and 
diagnostic modalities.[1] It can be regarded as the application of nanotechnology (i.e. the 
understanding and control of matter in the nano-size scale) in medicine.  
 
Figure 1.1. Size at the nanoscale. Nanomedicine faces with biological components in the micron/nanometer 
size, making interaction at the atomic scale. Scale on the right is logarithmic. 
Indeed, nanomedicine is an interdisciplinary field, where nanoscience, nanoengineering and 
nanotechnology interact with the life science to achieve improved patients’ outcome and quality of 
life.[3, 6] It also involves the design of colloidal materials and technologies for in vivo diagnosis and 
therapy, as well as new scaffolds and surfaces for regenerative medicine.[3] “The right size is 
Nanobiotechnology” was the statement by which Georges M. Whitesides in 2003 ventured that, by 
working together, physics and biology (from cellular to molecular biology, biochemistry and 
immunology) could have unlocked a fascinating way to lead the comprehension of the life 
mechanisms to an outstanding level of knowledge.[7] The enormous interest for understanding 
nanomaterials’ interaction with the “bio-world” relies on the certainty that they have the potential to 
contribute to new modalities in molecular imaging, sensing and therapeutic intervention.[8, 9] 
Nanomaterials along with chemistry would play a main role in this process. Indeed, chemistry places 
a bridge between physics and biology, making real the theoretical physical laws and taking back 
biology and biologist to reality. However, physics, biology and chemistry occupy just a small portion 
of the whole nanomedicine subject. Mathematical modelling and bioinformatics,[10] molecular 
dynamics[11], biomedical engineering[12] and microbiology[13] contribute as well to face the many 
problems and challenges related to nanomedicine. All together, these subjects optimize research, 
saving time and money. It is, by now, clear that nanomedicine is a multi- and interdisciplinary field, 
in which only the strict collaboration and reciprocal consideration of the different disciplines will 
succeed in tuning its many aspects. The nanotools here exploited have unique size- and shape-
dependent optical, electronic and magnetic properties, which are different from those of bulk 
materials of the same composition.[1, 3, 5] To date, several types of engineered nanomaterials have been 
developed, including both inorganic (e.g. iron oxide,[14] gold,[15] silver,[16] silica[17]), organic (e.g. lipid 
micelles,[18] polymeric nanostructures,[19] protein constructs,[20] layer-by-layer assemblies[21, 22]) or a 
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combination of them (Figure 2.1).[23] First, they can carry a large variety of drugs (e.g. doxorubicin[24-
26]) or therapeutic biological molecules (e.g. siRNA[27-29]) and protect them from degradation.[30] 
Moreover, since most of the drugs commonly used in standard therapy are slightly or sparely soluble 
in water[31] (e.g. cisplatin and docetaxel), the use of smart nanocarriers can enhance their 
biodistribution and prolong their circulation time.[32] Nanomaterials can also act as multiple drug 
carriers for a more effective therapy,[33-37] overcoming the multidrug resistance (MDR) expressed by 
many cancer cells,[38, 39] due to the possibility to target different metabolic pathways at the same time. 
The second important feature of the nanoparticles relies on their high surface to volume ratio, which 
allows for the grafting of multiple functional ligands at high density. These ligands can serve as 
stabilizing agents (e.g. PEG-based molecules[40]), for increasing the nanoparticles solubility and 
bioavailability,[41] or as targeting ligands (e.g. peptides,[42, 43] folic acid[44] or antibodies[45]) for the 
selective guidance of the nanocarriers to the desired cells or tissues.[46, 47] The third critical point 
regards the release of the loaded cargo in a controlled manner.[9].[48] Indeed, conventional therapy has 
sometimes tremendous side effects, related to the intrinsic toxicity of the therapeutic agent involved 
in the pathologic treatment.[48] Then, to spare the healthy tissues in favor of a more localized therapy, 
the so called precision medicine, has acquired enormous importance in modern medicine. Several 
therapeutic strategies based on nanoparticles were developed, all focused on the selective induction 
of damage to only unhealthy cells, minimizing the side effects of the anticancer drugs while 
enhancing the efficacy of clinical treatments.[4] 
 
Figure 1.2. Toolbox of the applications of nanoparticles in medicine. Several kinds of functionalization, 
from the addition of targeting ligands or diagnostic agents, to the conjugation with therapeutics, can make 
nanoparticles, of different sizes and compositions, suitable for a wide range of uses in nanomedicine CAFs = 









Cancer is not simply composed by homogeneous malignant cells but is rather a complex ecosystems 
containing tumor cells, and also endothelial, hematopoietic and stromal cells that influence its 
function as a whole.[49] There is increasing awareness that intratumoral heterogeneity contributes to 
therapy failure and disease progression[49] Cancers originally develop from normal cells that gain the 
ability to proliferate aberrantly and eventually turn malignant. These cancerous cells grow clonally 
and have the potential to metastasize.[50] The clonal origin of tumors does not imply that the original 
progenitor cell, that gives rise to a tumor, has initially acquired all of the characteristics of 
a cancer cell. On the contrary, the development of cancer is a multistep process in which cells 
gradually become malignant through a progressive series of alterations.[51]  The basis of cancer 
development is mainly genetic and involves the mutations and the selection for cells with 
progressively increasing capacity of proliferation, survival, invasion and metastasis.[51]  The tumor 
initiation results in genetic aberrations and abnormal proliferation of a single cell. New cell clones 
originate, with the further increase of genetic alterations that promote the cells heterogeneity. As the 
tumor progresses, modifications of the cellular environment take place. Different hallmarks of the 
cancer, intended as distinctive and complementary capabilities that enable tumor growth and 
metastatic dissemination, provide helpful fundaments to better understand what tumorigenesis is 
(Figure 2).[52] The remodeling of the extracellular matrix (ECM) is one of the main events of 
carcinogenic processes.[53-55] Indeed, ECM is composed of molecules like collagens, laminins, 
fibronectin, glycoprotein and proteoglycans that have a structural and functional role. The 
deregulation of all these components has been associated with the development of malignancies.[55-
57] Concomitantly to the induction of ECM remodelling processes, the cells of the tumor 
microenvironment secrete growth factors that promote angiogenesis, which is the formation of new 
blood vessels. Like normal tissue, tumors require nutrient and oxygen to sustain their growth. 
Angiogenesis, which occurs also during embryogenesis and wound healing in a transient manner, is 
deregulated in tumor and constantly activated.[52] Tumor-associated neo-vasculature rises in response 
to tumor-associated cells secreting growth factors that stimulate the proliferation of endothelial cells 
in the capillaries of the surrounding tissue, resulting in the outgrowth of new vessels.[57] Angiogenesis 
and tumor development may be associated with cancer cell migration form the original site. This 
event is promoted by the downregulation of adhesion molecules that ensure the contact between cell 
and ECM. The local invasion of the adjacent tissues is followed usually by the protrusion of those 
cells in the blood circulation, from which they can extravasate and start the growth of micrometastasis 
in distant tissues and organs. This colonization can lead to the establishment of a new tumor.[52] The 
chronic and often uncontrolled cell proliferation that represents the essence of neoplastic disease 
involves not only deregulated control of cell proliferation but also corresponding adjustments of 
energy metabolism in order to fuel cell growth and division.[52] As consequence, tumors sustain their 
growth in hypoxic environment, which produce a decrease of the pH of the surrounding vasculature 
and tissues. Another, still-unresolved issue surrounding tumor formation involves the role that the 
immune system plays in resisting or eradicating formation and progression of incipient neoplasias. 
The long-standing theory of immune surveillance proposes that cells and tissues are constantly 
monitored by immune system, responsible for recognizing and eliminating the majority of nascent 
cancer cells. According to this, solid tumors that do appear have managed to avoid detection by the 
Introduction. Nanoparticles in medicine 
6 
various components of the immune system or have been able to limit the extent of immunological 
killing, thereby evading eradication.[52] 
 
Figure 2.1. Cancer hallmarks. The distinctive features and properties of cancer development are highlighted. 
CAF = cancer associated fibroblast; CC = cancer cell; EC = endothelial cell; CSC = cancer stem cell; IC = 
immune inflammatory cell.[52] Adapted from Hallmarks of cancer: the next generation. Cell, 2011. 144(5): p. 646-74., Hanahan, 
D. and R.A. Weinberg, 2011, with permission from Elsevier. 
Half century of challenges 
Cancer is an abnormal growth of cells caused by multiple changes in gene expression leading to 
dysregulated balance of cell proliferation and cell death and ultimately evolving into a population of 
cells that can invade tissues and metastasize to distant sites, causing significant morbidity and, if 
untreated, death of the host.[58] This statement, proposed by Weinberg in “The biology of cancer” [58] 
masterfully resume the cancer concept. Cancers figure among the leading causes of death worldwide. 
Global demographic characteristics predict an increasing cancer incidence in the next decades, with 
19.3 million new cancer cases annually expected by 2025. An overview on the most recent data, 
shown in Figure 2.2, indicates the most common cancers estimated to occur in men and women by 
2016. Prostate, lung and bronchus, and colorectal cancers account for 44% of all cases in men, with 
prostate cancer alone accounting for 1 in 5 new diagnoses. For women, the 3 most commonly 
diagnosed cancers are breast, lung and bronchus, and colorectal, representing one-half of all cases; 
breast cancer alone was expected to account for 29% all new cancer diagnoses in women.[59] 
There has been a steady rise in cancer death rates in the western countries during the past 50 years. 
The major reasons of this increment may be found in the higher life expectancy, which has 
progressively risen over the last decades,[58]  and in the adoption of unhealthy lifestyles that became 
dramatically common with the achievement of economic welfare.[60] What has becoming clear is that 
cancer treatment was a more arduous challenge than what was initially expected. Despite the 
advancements of modern medicine in therapy and diagnosis, many patients still fail therapy, resulting 
in disease progression, recurrence, and reduced overall survival[49]. However, the continuously 
growing knowledge of molecular and tumor biology has notably changed cancer treatment paradigms 
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during the past 15 years.[61] Cancer therapy is moving gradually in the direction of more selective and 
safe treatments, aimed to reduce or avoid the destructive side effects of conventional therapies as 
surgery, radiotherapy and chemotherapy. New cancer treatment methods as genotype-directed 
precision oncology or targeted therapy, by means of antibody or other components of the immune 
system, are currently emerging and show a realistic possibility to be used in routine pharmacology.[61] 
However, in most of the cases conventional therapies are still cheaper and more efficient than the 
new arising technologies. Therefore, great efforts have to be made by researchers to develop the next 
generation of precision medicines with effective cost/benefit advantages.[61]  Besides the treatment of 
the disease once it is already established, the early diagnosis has remarkable importance. Until the 
second half of 20th century cancer was diagnosed only when symptoms could have been clearly 
recognized. In many cases, cancer would have already spread, thus limiting the efficacy of the 
treatment.[62] The poor outcomes for cancers diagnosed at advanced stages of development have been 
the main rationale behind research into techniques able to detect the disease before symptoms are 
manifest.[62] Besides the therapeutic treatment, nanomedicine has moved in the direction of 
developing efficient tools for the screening of cancer biomarkers at the early stages of tumor 
development.[63] 
 
Figure 2.2. Ten leading cancer types for the estimated new cancer cases and deaths by sex, in the United States 
by 2016. Reprinted, by permission, from Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal, Cancer statistics, 2016 Jan 7, 2016 
(24), Cancer Journal for Clinicians. Copyright © 1999 - 2017 John Wiley & Sons, Inc. 
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3. Magnetic materials 
... 
Introduction to magnetic nanoparticles  
Magnetic nanoparticles (MNPs), made by a metal core like iron, cobalt, manganese or metal oxides 
have been differently used in the development of modern technology.[64] In particular, in the last 
decades, MNPs have attracted the attention not only of researchers but also that of chemical and 
pharmaceutical companies focusing on applications in the biomedical field. The properties of such 
nanoparticles can be finely tuned depending on the desired application, which might range from 
medicine for MRI imaging,[65] drug delivery[66] and magnetic hyperthermia,[67] to bioremediation, for 
the removal of contaminants from wastewater[68]. Materials in the nano-size scale have physical-
chemical properties significantly different from those of the corresponding bulk materials, thanks to 
their high surface to volume ratio and tunable shape, composition and surface structure.[69] An 
important example of size-governed property change is related to magnetism. The attractive or 
repulsive forces between magnetic materials can be described in terms of magnetic dipoles, which 
can be considered as tiny bar magnets with opposite poles. Materials can thus be classified into 
diamagnetic, paramagnetic, ferromagnetic, ferrimagnetic, and antiferromagnetic according to the 
arrangement of their magnetic dipoles in the absence and presence of an external magnetic field.[70] 
Table 3.1 summarizes the different types of magnetic materials. 
Table 3.1. Features and behavior of the different types of magnetic materials. [70, 71]  
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Each magnetic moment shown for the different materials can be considered inside the same multidomain 
structure. Picture a shows the size-dependent difference between single domain and multidomain. Adapted, by 
permission, from U. Jeong,X. Teng,Y. Wang,H. Yang,Y. Xia, Superparamagnetic Colloids: Controlled Synthesis and Niche 
Applications, Dec 12, 2006 (28), Advanced Materials. Copyright © 1999 - 2017 John Wiley & Sons, Inc. 
Particle diameter
Single domain Multiple domains
a
Introduction. Nanoparticles in medicine 
9 
In general, magnetic materials refer to those characterized by either ferro- or ferrimagnetic 
features.[70] Different factors such as saturation of magnetization (Ms), coercivity (Hc), blocking 
temperature (TB) and relaxation time (τN and τB) contribute to control and optimize the key magnetic 
properties of MNPs.[71] Ms is the maximum magnetization possible and arises when all the magnetic 
dipoles are aligned in an external magnetic field. This parameter increases with nanoparticles size 
until it reaches the bulk value.[71] Figure 3.1a shows a typical magnetization curve for ferromagnetic 
or ferrimagnetic nanoparticles, showing the remanent magnetization (Mr, induced magnetization, 
which is conserved after an applied field is removed) and coercivity (Hc, the intensity of an external 
magnetic field needed to force the magnetization to go back to zero).[70] Magnetism, which arises 
from the collective interaction of atomic magnetic dipoles, is highly volume and temperature 
dependent. When the size of a ferro- or ferrimagnet decreases to a certain critical value rc, the particles 
change from a state with multiple magnetic domains to a single domain.[71] In a single domain 
material, the magnetic moments of the atoms align accordingly to the reciprocal interactions below a 
critical temperature (TB). Blocking temperature defines the transition from ferromagnetic to 
superparamegnetic regimes and can be considered as the thermal energy needed for spin 
reorientation.[70, 72] As shown in Figure 3.1b, if the size decreases to a value r0, the thermal energy 
becomes comparable to that required for flipping the magnetic moment in the opposite directions, 
leading to the randomization of the magnetic dipoles in a short period of time.[70] Such small particles, 
known as superparamagnetic nanoparticles, do not have permanent magnetic moments in the absence 
of an external field and behave like a giant paramagnetic “molecule” in which the magnetic moment 
is able to rotate randomly. Nevertheless, they can respond fast to an external magnetic field.[70]  As a 
consequence, the magnetization changes spontaneously above a critical temperature, which is 
significantly lower than in the case of single domain materials and approximate the room 
temperature.[64, 70, 73] Indeed, TB increases with particle size.
[71] The limiting size between 
monodomain and superparamagnetic MNPs (SPIONs) depends on their crystalline structures (in 
particular anisotropy constant K), composition and size.[64, 70] Figure 3.1c shows the maximum 
diameters for superparamagnetic (Dsp) and single-domain (Dsd) nanoparticles of different 
compositions [71, 72] and Figure 3.1d their magnetization curves. While for multidomain or single 
domain ferromagnetic nanoparticles a hysteresis loop is produced due to the presence of several 
magnetic moments that affect Mr and Hc (red line), for superparamagnetic nanoparticles, a sigmoidal 
curve with no hysteresis is originated (green line). In addition, the curves of diamagnetic (black line) 
and paramagnetic (blue line) nanoparticles are shown, with opposite or weak response to magnetic 
field, respectively.[71]The lack of remanence magnetization enables superparamagnetic nanoparticles 
to maintain their colloidal stability and avoid agglomeration, which is very important for biomedical 
purposes:[64] The main biomedical applications include magnetic hyperthermia (MH),[74] MRI 
imaging[75-77] and magnetic separation[44, 78] and will be discussed in paragraph 4.  
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Figure 3.1. a) The typical magnetization curve of a ferro- or ferrimagnetic material, from which one can 
identify the saturation magnetization Ms, the maximum value of M; the remanence magnetization Mr, the 
residual magnetization at zero field strength; and the external field required to bring magnetization back to 
zero known ascoercivity Hc,.[70] b) Schematic illustration of the dependence of magnetic coercivity on particle 
size. In the single-domain regime, the coercivity can follow either the solid curve for non-interacting particles 
or the dashed line for particles that have coupling between them. The coercivity falls to zero for 
superparamagnetic colloidal particles.[70] c), Different magnetic materials have different transition size from 
single domain (Dsd, diameter single domain) to superparamagnetism (Dsp, diameter superparamagnetism). For 
diameters, D < Dsp, they exhibit superparamagnetic behaviour; for D > Dsd, they split into multiple domains to 
minimize their overall energy and in between, Dsp < D < Dsd, they are ferromagnetic and single domain.[72] d) 
Magnetic behavior, under the influence of an applied field, for different magnetic materials. The X-axis is the 
applied field (Oe), and the Y-axis is the magnetization of the sample as a function of field exposure (emu/g). 
Typical behavior of multidomain ferro(i)magnetic materials shows hysteresis loop (red line); single domain 
materials/superparamagnetic nanoparticles do not show hysteresis and have coercivity close to 0 (green line). 
Paramagnetic materials slightly follow the external magnetic field (blue line), while diamagnetic materials 
respond in the opposite direction of the applied field (black line). (a-b) Reprinted, by permission, from U. Jeong,X. 
Teng,Y. Wang,H. Yang,Y. Xia, Superparamagnetic Colloids: Controlled Synthesis and Niche Applications, Dec 12, 2006 (28), 
Advanced Materials. Copyright © 1999 - 2017 John Wiley & Sons, Inc. (c-d) Reprinted, with permission, from Krishnan, K.M., 
Biomedical Nanomagnetics: A Spin Through Possibilities in Imaging, Diagnostics, and Therapy, IEEE Transactions on Magnetics, 
2010. 46(7): p. 2523-2558. 
MNPs: iron oxide nanoparticles above all 
Among the different kinds of magnetic nanoparticles developed so far, iron oxide-based nanoparticles 
(IONPs) are the most used for biological applications. Indeed, IONPs express the best compromise 
between good magnetic properties (such as Ms) and stability under oxidizing conditions.
[64] The most 
investigated iron oxides are FeO (wuestite), γ-Fe2O3 (maghemite) and Fe3O4 (magnetite), which have 
remarkably different magnetic properties.[70] Wuestite, being paramagnetic at room temperature, is  
less attractive than maghemite and magnetite. Nevertheless, new opportunities begin to emerge for 
nanoparticles with a mixed composition of wuestite and ferrimagnetic oxides, as it will be discussed 
in chapter 6. γ-Fe2O3 and Fe3O4 are instead ferrimagnetic
[79] Both have spinel structure, with the 
oxygen ions forming a close-packed cubic lattice and iron ions located at the interstices.[64, 80] The 
saturation of magnetization (Ms) for bulk material, at low temperature (ca. 5 K), is higher for 
magnetite (98 emu/g) than for maghemite (83.5-87.4 emu/g). The highest value reached so far for 
magnetite IONPs was 92 emu/g, while for maghemite it was 77 emu/g.[81] Despite the better magnetic 
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properties, magnetite is poorly stable under ambient conditions.[73] Indeed, Fe3O4 nanoparticles tend 
to oxidize to γ-Fe2O3, which instead are more stable in aqueous solution, ensuring durable magnetic 
performances.[64, 73] Several methods for the synthesis of IONPs were developed and are now 
available. Table 3.2 reports the procedures used for the synthesis of iron oxide nanoparticles.[73, 80, 82, 
83]  
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In addition to the methods shown in Table 3.2, other synthetic routes can be identified: sol-gel and polyol 
method, microwave-assisted synthesis, sonolysis or sonochemical methods, electrochemical methods, 
aerosol/vapor methods, electron beam lithography, gas-phase deposition, oxidation method, flow injection 
method and supercritical fluid method.[73] 
Among all the listed synthetic approaches, one of the most studied for the synthesis of IONPs is 
thermal decomposition of iron-oleate, developed by Hyeon et al.[92, 93] due to its scalability and 
versatility. However, a variety of parameters (e.g. atmosphere, the amount and type of reducing agent, 
surfactant, precursor, solvent) make this type of synthesis quite critical. Monitoring the effect of those 
factors on the magnetic behavior, as well as on the size and shape distributions, is of great relevance 
for developing suitable IONPs for biomedical applications.[81] During the synthesis, the IONPs are 
covered by capping ligands, which contribute to separate the magnetic domain of each single 
nanoparticle and to hold the attractive forces apart.  For both the syntheses preformed in  aqueous or 
organic solvents the binding of the capping ligands to the IONPs surface is mediated by coordination 
complex between the electron donor groups (e.g. carboxylic,[86] hydroxyl,[94] phosphonate[95] or amine 
groups[96, 97]) and Fe2+ and Fe3+ species (Figure 3.2a).[98] Because iron is extremely reactive towards 
oxidizing agents and in the presence of water, the protection of MNPs is of prime importance for 
obtaining physically and chemically stable colloidal systems. Such protection can be achieved by: 1) 
surface coating of the MNPs (Figure 3.2b), using polymeric stabilizers/surfactants, like dextran,[99] 
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carboxydextran,[100] poly(vinyl alcohol) (PVA)[101] or poly(ethylene glycol) (PEG);[102] 2) by 
deposition of layers of metals (e.g. gold)[103] or oxides(e.g. SiO2);
[104] ,3) by the formation of lipid-
like coatings (liposomes/ lipid NPs)[105, 106] around the magnetic core.[80] All the three listed cases can 
lead to the formation either of single-coated nanoparticles or clusters. Since many of the synthetic 
routes produce nanoparticles soluble in organic solvents, surface functionalization of IONPs with 
water-soluble ligands or polymers is crucial for their bio-applications. The surface coating strategy 
can involve: 1) the replacement of the capping ligands with more strongly binding ligands, usually 
referred as ligand exchange, Figure 3.2c, which increases the nanoparticles solubility in aqueous 
media;[107] 2) the addition of amphiphilic molecules, which express affinity for both the hydrophobic 
component of the nanoparticle surfactants and for the aqueous surrounding environment known as 
polymer coating, Figure 3.2c[107, 108]. Besides improving the colloidal and physical stability of the 
particles, the surface coating may provide the scaffold for further conjugation of bioactive molecules 
or targeting ligands  in order to obtain multifunctional MNPs (Figure 3.2d).[80]  
 
Figure 3.2. Surface coating provides stability and functionalization to IONPs. a) Nucleation process with 
different surfactants. b) Just after the crystal growth or in a second step of synthesis, IONPs can be coated with 
several molecules able to prevent the degradation of the inorganic iron core. c) Ligand exchange (LE) or 
polymer coating (PC) are the two main techniques used for stabilizing the nanoparticles in aqueous media. d) 
The functionalization with biomolecules such as enzymes, proteins, antibodies, small bioactive molecules (e.g. 
folic acid or biotin) or carbohydrates makes IONPs able to interact with the biological environment. (a) Adapted 
from (Ref 97) with permission of the Royal Society of Chemistry. (b) Adapted with permission from L. Harivardhan Reddy, José L. 
Arias, Julien Nicolas, and Patrick  Couvreur, Magnetic nanoparticles: design and characterization, toxicity and biocompatibility, 
pharmaceutical and biomedical applications. Chem Rev, 2012. 112(11): p. 5818-78. Copyright © 2012 American Chemical Society.  
An important feature of this particular type of MNPs, i.e. IONPs, is their significantly lower toxicity 
and good biodegradability, which show outstanding compatibility towards biological systems, both 
in vitro and in vivo.[109]  As result, the US Food and Drug Administration (FDA) and the European 
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Medicines Agency (EMA) have already approved the medical use of several magnetic iron oxides 
nanoparticles (Table 3.3).[110]  
Table 3.3. Approved and available pharmaceuticals IONPs-based.[80, 110] 
Compound/trademark Company Material Application Target 
Nanotherm® MagForce 
Aminosilane-coated 
IONPs, 15 nm 
Hyperthermia Glioblastoma 












anemia in adult 
patient with 
CDK 






























SPION = superparamagnetic iron oxide nanoparticle; CDK = chronic kidney disease; FDA = Food and Drug 
Administration (USA); EMA = European Medicines Agency; PMDA = Pharmaceuticals and Medical Devices 
Agency (Japan); RES = Reticuloendothelial system. 
many other compounds, initially approved for clinics, were subsequently withdrawn from the market 
due to emerging adverse effects or reduced market potential. Examples of these pharmaceuticals are: 
Abdoscan®, 300 nm IONPs used as gastrointestinal contrast agent; Clariscan®,[114] oxidized starch-
coated SPIONs replaced on the market by a gadolinium-based contrast agent; Sirenem® 
(Combidex®)[115] dextran-coated SPIONs used as contrast agent to detect metastatic diseases in lymph 
nodes; Resovist®, carboxydestran-coated SPIONs contrast agent for liver imaging.[116] Remarkably, 
almost the all the listed IONPs-based systems are explored for MRI or iron deficiency therapy. Thus, 
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4. IONPs applications 
… 
Magnetic separation 
Magnetic separation (Figure 4.1) can be used as a quick and simple method for the efficient and 
reliable capture of proteins, biomolecules (DNA and RNA), mammalian cells, bacteria and virus.[73] 
The switchable magnetization properties of nanoparticles, particularly those from superparamagnetic 
nanoparticles, enable the magnetically-driven transport of biological molecules.[70]  Biological 
entities exploit specific interactions with high affinity between molecular pairs to achieve reciprocal 
recognition and trigger signaling processes.[64] Thus, the surface of the nanoparticles is modified with 
biocompatible and/or targeting molecules. The first ones refer to PEGs, carbohydrates or 
phospholipids, which provide good colloidal stability, while the second is obtained using 
antibodies[117] or small molecules like folic acid or biotin,[118] which confer different degrees of 
specificity and affinity towards the desired biological specie.[70] Several applications for bio-
functionalize MNPs have been found so far, including protein and DNA separation, molecular 
biosensing and pathogen detection/sequestration.[64] The separation and enrichment of biologically 
relevant molecules/cells allow a fast and accurate identification of determinant markers inside a 
complex biological fluid, increasing the sensitivity of the commonly used analytical devices like flow 
cytometer[119, 120].  
 
Figure 4.1. Magnetic separation. a) MNPs, functionalized accordingly to the desired research purpose, are 
incubated with the biological tissue of interest (1). Here, nanoparticles are able to recognize specifically their 
target. Subsequently, they can be collected by applying an external magnetic field (2). The magnetically 
isolated and enriched biomolecules (cells, proteins, antigens etc.) can be separated from the MNPs and washed, 
in order to remove debris (3). Once re-dissolved in the desired medium, the sample can be analyzed using the 
commonly used analytical techniques, like Fluorescence Activating Cell Sorting (FACS) (4). b) MACS® 
columns contain a matrix composed of ferromagnetic spheres covered with a cell-friendly coating that, when 
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placed on a magnetic separator, amplify the magnetic field and are able to hold cells magnetically labeled with, 
for example, MNPs. The unlabeled fraction is quickly eluted, while the desired labeled population of cells is 
collected just after the removal of the column from a compatible magnet. c) Stand for supporting the magnetic 
separator that fixes the magnetic columns of different sizes. 
Nowadays, several magnetic tools based on magnetic micro/nano particles have been 
commercialized.[121] Among them, Dynabeads® (Invitrogen)[122] and MACS® microbeads (Miltenyi 
Biotech) can be considered the most popular.[123] Dynabeads® are uniform polystyrene beads with a 
magnetic core and dimeter of 4.5 µm, while MACS® (Figure 4.1b) microbeads are beads of 20-100 
nm made by superparamagnetic iron oxide nanoparticles covered by a dextran coating. Opportunely 
functionalized with biological active molecules, they found important applications in the isolation of 
immune system cells and cells from bulk tissues. [124-127] 
Magnetic Hyperthermia 
Magnetic hyperthermia (MH) is a novel non-invasive treatment, now undergoing clinical trials on 
patients affected by glioblastoma multiforme, prostate cancer and pancreatic cancer.[64, 128] It exploits 
the heat generated by magnetic nanoparticles (MNPs) when exposed to an alternating magnetic field 
(AMF) (Figure 4.3).[8, 72, 129] The continuously switching rotation of the magnetic moment of the 
nanoparticles under AMF generates energy, which is dissipated in the form of heat. In small 
monodomain MNPs, the reorientation of the magnetic moments can occur due to Néel or Brownian 
relaxation. Néel relaxation (with time constant τN) occurs when the inner magnetic spin flips from the 
easy axis of the crystal structure to the opposite direction, thus overcoming the energy barrier related 
to magneto-crystalline anisotropy constant (K) and particle magnetic volume (Vm). In addition, it is 
insensitive to the viscosity (η) of the environment. Brownian relaxation involves the mechanical 
rotation of the whole particles, constituted by the magnetic core and the organic coating. Its time 
constant (τB) strictly depends on the viscosity (η) of the medium and the hydrodynamic size (dh) of 
the particle.[64, 71] Figure 4.2 shows the relaxation mechanisms involved in the dissipation of heat 
from the nanoparticles.  
 
Figure 4.2. Relaxation mechanisms for nanoparticles. Néel (top) and Brownian (bottom) rotation of the 
nanoparticles. Red dot and orange square refers to biomolecules grafted on the NPs coating. The equations 
show the magnetization energy barrier (1), the Brownian (2) and Néel (3) relaxation times and the overall 
effective relaxation time of the particles (4). ΔE = thermal energy barrier; K = anisotropy constant; Vm = 




                     (2) 
τN = τ0exp (
𝐾𝑉
𝐾𝐵𝑇




                    (4) 
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magnetic volume; η = viscosity; VH = hydrodynamic volume of the particle; KB = Boltzmann constant; T = 
temperature; τ0 = 10-9 s.[130] 
The heating efficiency of the magnetic nanoparticles is expressed by their specific absorption rate 
(SAR)/specific loss power (SLP). [8, 64, 71, 130] The SAR value defines the temperature increase with 










        (5) 
where C is the specific heat capacity of the solvent. The concentration m of magnetic material is 
expressed as gL-1. [86, 131] SAR depends on various factors, among them: 1) the applied magnetic field 
characteristics (frequency and amplitude); 2) the intrinsic magnetic properties (i.e. saturation 
magnetization, anisotropy); 3) the properties of the dispersing medium (i.e. viscosity, concentration, 
heat capacity).[128] From a biological point of view, hyperthermia is defined as the use of heat for 
killing tumors. [8] When biological tissues are exposed to temperatures higher than 41°C, damages are 
induced in cancer cells rather than healthy cells, due to the disorganized and compact vascular 
structure of the tumor mass, which hinders heat dissipation in comparison to healthy tissues.[8, 64, 130] 
Some medical constraints are imposed to the physical parameters of the AMF to ensure a  safe 
application of hyperthermia to patients. Indeed, the product of the frequency by the magnetic field 
amplitude (Hf) cannot exceed an established threshold of 5 x 109 Am-1s-1.[130, 132]  
Gilchrist et al. were the first ones to use magnetic particles for the thermal treatment of tumors, back 
in 1957. In this pioneer work, they successfully used micrometer-size particles for heating lymph 
nodes in dogs.[133]  The successful results obtained from MNP-based hyperthermia treatment of cancer 
in animal models, in the past three decades,[134-138] led to the establishment of the technique in clinical 
and industrial development.[64] Clinical studies, using combined hyperthermia and radiation therapy 
or chemotherapy, have shown that more than 80% of patients had tumor regression, of which 37% 
had a complete tumor ablation while 25% exhibited a tumor reduction above 50%.[64, 139] The efforts 
made in this field culminated with the approval of the therapy by FDA for use in the treatment of 
established non-surgical cancer additive treatments. [64, 139]   
 
Figure 4.3. Magnetic hyperthermia application. a) Hyperthermia carried out using iron oxide nanoparticles 
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release energy in the form of heat, rising the surrounding tissue temperature up to 42-45 °C, thus promoting 
the disease ablation. b) Picture of the device used for measuring the heating performance of the nanoparticles 
in vitro (DM applicator series from nanoScale Biomagnetics Corp.). The probe, submerged in a solution of 
IONPs, is inserted inside the equipment coils able to generate AMF. The increase of temperature over time is 
recorded by the analyzer and the SAR values calculated according to the slope (ΔT/Δt) obtained. c) 
Hyperthermia experiment on a mouse using similar instrumentation. Usually, the tumor xenografted into the 
mouse is locally injected with the nanoparticles and then exposed to cycles of AFM.[140] d) Thermotherapy 
treatment of the pelvic region in humans, after intratumoral injection of magnetic nanoparticles, using the 
alternating magnetic field applicator MFH 300F (MagForce Nanotechnologies AG, Berlin, Germany).[141] (c) 
Reprinted, by permission, from Hayashi K, Nakamura M, Sakamoto W, Yogo T, Miki H, Ozaki S, Abe M, Matsumoto T, Ishimura K. 
Superparamagnetic Nanoparticle Clusters for Cancer Theranostics Combining Magnetic Resonance Imaging and Hyperthermia 
Treatment. Theranostics 2013; 3(6):366-376.  Creative Commons License. (d) Reprinted, by permission, from Thiesen, B. and A. 
Jordan, Clinical applications of magnetic nanoparticles for hyperthermia, International Journal of Hyperthermia, 2008. 24(6): p. 467-
474. Copyright © Taylor & Francis. 
Although different kinds of MNPs can be efficiently used for hyperthermia purposes,[64, 70, 130] ferrite 
nanomaterials like CoFe2O4
[142, 143] and MnFe2O4
[131], IONPs remain the main candidates, due to their 
higher heat performance.  However, the intrinsic toxicity of Co2+ and Mn2+ [144, 145] can instill 
skepticism in the use of these materials for therapy, especially when it requires multiple exposures 
and prolonged circulation in the body of the nanoparticles. Contrarily, the superior biodegradability 
and biocompatibility of IONPs make these nanoparticles absolutely promising.[146] Nowadays, there 
are two main companies developing devices for MNP-based hyperthermia for clinical application: 
Sirex Medical and MagForce. Sirtex Medical designed a combined hyperthermia-radioteherapy 
system, using small magnetic micro-spheres (Thermosphere®, under development in collaboration 
with the Australian National University) in combination with resin-based microparticles impregnated 
with radioisotope yttrium-90, for the treatment of liver cancer.[64] Under magnetic induction 
conditions of 53 kHz and 30 kAm-1, an intratumoral temperature of 48 °C can be reached in 5 
minutes.[147] MagForce exploits iron oxide nanoparticles, with a diameter of 15 nm, coated with 
aminosilane for the treatment of cancer such as glioblastoma, prostate and pancreatic cancer.[64, 141, 
148, 149] Using an applicator MFH®300F generating frequency of 100 kHz and fields between 0-18 
kAm-1, intratumoral treatment reaches temperatures ranging from 43 °C to 47 °C, at an injected dose 
of nanoparticles between 40-120 mg mL-1 (Figure 4.3d).[141, 150, 151] Despite these encouraging results, 
concerns have been raised regarding the toxicity for cancer-directed therapy, due to the possible 
thermal damaged to the adjacent healthy tissues. In order to minimize the potential side effects arising 
during the clinical treatments, the quantity of nanoparticles administered needs to be as low as 
possible.[152] Currently, this represents the main limitation of MH, i.e. is the poor heating efficiency 
of most of the used magnetic nanoparticles when administered at low doses.[152] Another drawback 
which comes from the high concentration of IONPs required for therapy is the impairment to monitor 
tumor progression by MRI, since the substantial dose of IONPs is incompatible with MRI 
imaging.[153] Although several research studies have aimed to design optimal heat mediators that 
would allow reduction of the IONPs dose, while maintaining the required heating performance, low 
heating efficiency remains among the current limitations for IONPs used in clinical trial.[154] 
Therefore, major efforts were made to optimize the NP heating efficiency by tuning key magnetic 
parameters such as size, shape and composition. 
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Nanoparticle’s shape matters for hyperthermia: the importance of using 
nanocubes 
Anisotropic-shaped magnetic nanoparticles have attracted enormous attention in the last few years 
owing to their superior magnetic properties.[128] The particles heat dissipation strongly depends on 
their physico-chemical features. Thanks to the advancements in thermal decomposition synthesis, in 
the latest decades a significant progress in size and shape control has made possible to obtain a large 
variety of spherical,[93] cubic,[155] star-,[156] flower-,[157] rod-[158] and octapod-shaped[159] iron oxide 
nanoparticles.[128] Recently, it was reported that anisotropic cubic-shaped particles reveal a superior 
heating performance in comparison to spherical ones..[152, 160]  In particular, for 19 nm nanocubes 
(NCs) higher SAR values and higher saturation of magnetization values (Ms) were determined than 
for spherical IONPs of near size (25 nm).[161] Interestingly, the SAR values displayed by iron oxide 
nanocubes (with effective anisotropy constant Keff = 9.1 x 10
4 J/m3, and Ms = 1.7 x 106 Am-1) are 
among the highest reported in the literature so far for IONPs. In detail, the SAR value found was 
about 3000 W/g at µ0Hmax = 73 mT (58 kAm
-1) and f = 274 kHz.[152] Nevertheless, the synthesis of 
monodisperse NCs remains a great challenge and it is hardly attainable by any other method rather 
than high temperature colloidal synthesis.[128] The synthesis based on metal-organic precursors, using 
iron acetylacetonate,[81, 132, 153, 160] has proven to be successful for the preparation of homogeneous 
NCs, with tunable sizes (Figure 4.4a). However, among the different NCs sizes obtainable, Guardia 
et al.[162] demonstrated that nanocubes of 19 nm have the best heating performances in the biological 
threshold of frequency and field applied. Compared to bigger nanocubes of 25, 35 and 43 nm, 19 nm 
nanocubes show no hysteresis, with magnetic coercivity close to 0 Oe.[161, 162] Despite they appear to 
be the best candidate for designing a IONPs-based strategy for hyperthermia treatment, another 
parameter affecting the heating performance of the nanocubes has to be considered. As demonstrated 
by Fortin et al.,[163] viscosity (η) is a physical parameter that affect the nanoparticles heating 
efficiency. In addition, Cabrera et al. confirmed a strong decrease of the heat dissipation dependent 
on the increase of the medium viscosity when considering iron oxide nanocubes (Figure 4.4b).[164] 
In addition to the viscosity dependent SAR behavior due to the interaction of magnetic nanoparticles 
with biological samples, it has been shown that the magnetic heating efficiency is significantly reduce 
when MNPs are located inside cells or tissues.[67, 165] this might be explained by the increase of 
viscosity and/or nanoparticles aggregation imposed by the host biological matrices.[165] Hence, the 
need for nanoparticles able to retain their heating efficiency inside the biological environments, in 
order to obtain the maximum therapeutic effect from the hyperthermia treatment, has become a clear 
goal. Noteworthy, the viscosity dependent heating efficiency was also proved for spherical IONPs, 
which present lower SAR values in high viscosity media compared to nanocubes, within a size below 
30 nm,.[161] Indeed, while for spherical IONPs the SAR values strongly decrease when increasing the 
viscosity of the medium, for 14 nm nanocubes SAR is constant among the different viscous media 
tested.[165] Even if 14 nm ones have lower heating performances, compared to the 19 nm 
nanocubes,[162] their viscosity independent behavior suggests their use in hyperthermia application on 
biological samples.[165]. 
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Figure 4.4. Iron oxide nanocubes. a) Representative transmission electron microscopy (TEM) images at low 
(left panel) and higher (right panel) magnification of iron oxide nanocubes for nanocubes edge with lengths of 
(1-2) 12 nm and (3-4) 19 nm. Scale bar 100 nm (left) and 50 nm (right). b) Viscosity dependence of SAR 
values for 14 nm (black dots) and 24 nm (orange dots) IONCs and 21 nm CoFeNCs (green dots). a) Reprinted 
with permission from Pablo Guardia, Riccardo Di Corato, Lenaic Lartigue, Claire Wilhelm, Ana Espinosa, Mar Garcia-Hernandez, 
Florence Gazeau, Liberato Manna, and Teresa Pellegrino, Water-Soluble Iron Oxide Nanocubes with High Values of Specific 
Absorption Rate for Cancer Cell Hyperthermia Treatment. ACS Nano, 2012, 6 (4), pp 3080–3091. Copyright © 2012 American 
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5. Iron oxide nanoparticles for multimodal cancer therapy  
… 
Cancer treatment: a multimodal approach 
Considering the promising features of using IONPs for MH cancer treatments, new multimodal 
strategies for these materials might be envisaged. One of the most prominent is the addition of binding 
biomolecules to the nanoparticles surface to provide specificity and selectivity and/or the combination 
of MH with drug delivery. Thus, it might be possible to improve the accumulation of the IONPs at 
the tumor site and confine the thermal treatment exclusively to the malignant tissue, sparing the 
healthy ones. In addition to the target units, the surface might be also coated with polymers able to 
encapsulate drug molecules and enhance the effectiveness of cancer therapy. The drug release might 
be driven by a thermic stimulus generated by the magnetic nanoparticles under magnetic 
hyperthermia. When administered in the body, nanoparticles should circulate in the blood as long as 
possible to have a higher chance to find their cell target. To do so, their stability and the protection of 
both targeting molecules and loaded cargo must not be compromised. Once the IONPs will recognize 
the tumor cells, they are expected to be internalized and to release their therapeutic cargo enhanced 
by MH. To direct nanoparticles towards tumor cells, implies overcoming several biological barriers, 
as shown in Figure 5.1. 
 
Figure 5.1. NPs in the body. Overcoming the biological barriers. Despite their potential for targeting and 
drug delivery purposes, the nanoparticles face a complex series of biological barriers that severely limit site-
Introduction. Nanoparticles in medicine 
21 
specific bioavailability, preventing achievement of proper therapeutic outcomes. These obstacles include 
opsonization and subsequent sequestration by the mononuclear phagocyte system (MPS) and 
reticuloendothelial system components (RES) (1), nonspecific distribution (2), degradation and elimination 
from the body by the clearance organs and tissues (3), cellular internalization and escape from endosomal and 
lysosomal compartments (4). MP = macropinosome; CLIC/GEEC = clathrin-independent carrier/ 
Glycosylphosphotidylinositol - anchored protein (GPI-AP) enriched compartment; CCP = clathrin-coated pit; 
CAV = caveolin; EE = early endosome; LE = late endosome; LY = lysosome; TGN = trans Golgi network; 
PNRE = perinuclear recycling endosome. 
Bioactivity and biodistribution of nanoparticles 
For iron oxide nanoparticles, as well as for most of MNPs, different physical-chemical parameters of 
the material affect the biodistribution of the nanoparticles in human body. Nanoparticles size for 
instance is one of the main features to be considered when designing a therapeutic strategy against 
cancer. The adsorption of plasma proteins (protein corona)[166, 167] onto the NPs was shown to be 
lower for smaller nanoparticles (6% of plasma proteins adsorbed onto 80 nm NPs) than for bigger 
ones, with an trend increase trend dependent on the nanoparticles size (23% and 34% of plasma 
proteins adsorbed onto 170 nm and 240 nm particles).[80] This has important consequences for the 
clearance of the nanoparticles promoted by the cells of the reticuloendothelial systems (RES) and, in 
particular, by monocytes circulating in the blood (mononuclear phagocyte system, MPS), 
macrophages located in different organs (like liver, spleen, lymph nodes, bone marrow, lung an brain) 
and Kupffer cells in the liver.[168-170] Thus, the systemic clearance of the smaller nanoparticles was 
slower than that of the bigger NPs.[80] Moreover, the nanoparticles within a size above 200 nm 
undergo filtration in the spleen, whereas particles with sizes less than 100 nm have higher probability 
of getting trapped into the hepatic parenchyma.[80] Very small particles, below 8 nm of diameter, are 
instead filtered by the glomerular capillary membrane of the renal tubules and cleared by the kidneys 
through the urine.[169]  
Another key parameter, which affects the biodistribution of nanoparticles, is the surface charge. Even 
if it is reported that neutral nanoparticles have low level of opsonization thus showing an extended 
circulation time, [80, 169] the absence of charge and consequently electrostatic repulsions might 
promote the aggregation of IONPs in vitro.[171] This, in turn, might compromise   the nanoparticles 
circulation in the blood system, the effectiveness of drug delivery as well as the hyperthermia, since 
aggregation drastically compromises the heating performance of the IONPs. [171] Therefore, designing 
charged IONPs is preferable. Usually, IONPs with surface charge below -20/-30 mV or above 
+20/+30 mV present good colloidal stability. Negatively charged IONPs shows hepatic and splenic 
uptake but generally a higher blood circulation compared to positively charged nanoparticles that tend 
to be rapidly cleared from the systemic circulation.[80, 169] Another interesting behavior for differently 
charged nanoparticles was reported by Rotello’s group.[172] Using an in vitro system simulating the 
complex tumor environment, they showed that 6 nm spherical gold nanoparticles, with negative or 
positive charges of +30 mV and -36 mV, respectively, were able to rapidly penetrate the cell mass. 
Interestingly, while positive nanoparticles interacted fast with the surrounding cells, negative 
particles were able to go deeper in the tumor mass.[172]  
Along with size and surface charge, shape plays also a major role for the biodistribution of NPs in 
the body. It has been shown that rod-shaped and non-spherical nanoparticles exhibit a longer blood 
circulation time compared to spherical ones, in rat model studies.[173] In particular, short-rod 
mesoporous silica nanoparticles, which have roughly a spherical profile, were found to accumulate 
in the liver, whereas long-rod-shaped particles accumulated into the spleen. Moreover, short-rod 
mesoporous silica nanoparticles showed a faster clearance rate via urine and feces compared with 
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long-rod mesoporous silica nanoparticles.[174] This behavior is likely to be explained based on the 
different interactions that rod-shaped and spherical nanoparticles have with macrophages.[175] In 
addition, the surface organic coating of the particles can dramatically change the composition of the 
protein corona.[169, 170] Noteworthy, the coating should be non-toxic and biodegradable in order to 
ensure safety of the IONPs in clinics. Besides using several polymeric coatings,[176, 177] which should 
provide biological activity while reducing the clearance and the non-specific proteins adsorption, 
recently, new strategies were developed for increasing the biodistribution and the “blood-
compatibility” of the nanoparticles. For instance, the development of biomimetic coatings consisting 
of cell membrane portions isolate from leukocytes[178] and red blood cells[179] demonstrated a 
decreased uptake rate by the MPS, RES and Kupffer cells and so a prolonged circulation time in the 
blood.[178, 179] Other approaches focus on the beneficial effects of the protein corona formation for 
modulating nanoparticles stability and drug delivery.[180] Hamad-Schifferli and co-workers 
demonstrated the efficient formation of controlled protein corona around gold nanoparticles of 
different shape.[181, 182] The protein scaffold was used for payloading cargo molecules such as DNA 
or doxorubicin and their passive releasing.[181, 182] However, since protein corona is a very dynamic 
process relying on the presence of different proteins and their relative concentration in the serum, the 
effectiveness of this approach has to be demonstrated in vivo before being accepted as an alternative 
method.[183] Given all the parameters discussed, one can conclude that the NPs clearance mechanism 
is a very complex and hardly predictable phenomenon, which must consider the combination of  
several factors such as size, charge, shape and coating.[170] It is of utmost importance that particles 
remain stable while in circulation in order to prevent non-required activity in undesired organs and to 
maximize bioavailability at the targeted site.[184] However, once they have accomplished their 
therapeutic purpose, IONPs should leave the organism in a safe way without affecting the body 
homeostasis. Indeed, one of the main concerns is related to the problems that can arise from a long-
time persistence of the nanomaterials in the body: they can trigger chronic inflammation upon the 
interaction of the partially degraded NPs with the immune system or the generation of toxic by-
products.[146] Specific methodologies for monitoring the fate of iron oxide nanoparticles in complex 
organisms are the following: electron paramagnetic resonance (EPR), which allows to distinguish at 
room temperature IONPs from endogenous paramagnetic iron species, MRI, magnetic manipulation 
of the nanoparticles inside organs or tissues, transmission electron microscopy (TEM) and elemental 
analysis.[146] As general rule, the fraction of IONPs that do not reach the liver, spleen or kidneys, 
accumulates inside the endosomal/lysosomal organelles of the cells where they undergo degradation 
processes (Figure 5.2a and d). During iron oxide dissolution, IONPs become surrounded by ferritin 
proteins, which are deputed to the storage and transportation of endogenous iron in the body (Figure 
5.2d). Since ferritin regulates the metabolism of iron species, which can be deleterious if not 
opportunely complexed, the colocalization of the protein with the IONPs suggests remediation and 
recycling processes, ensuring the innocuousness of the nanoparticles.[146] In addition, it was shown 
that the IONPs aggregation state influences the degradation rate of the iron oxide, with single and 
isolated nanoparticles that erode faster than aggregated ones.[146] In mouse model studies, Kolosnjaj-
Tabi et al. could follow the degradation of IONPs by following the reduction of MRI contrast of 
nanocubes in spleen and liver over  time, which returned to normality after four months post-
intravenously (i.v.) injection (Figure 5.2b).[132] In this work the sequestration of the iron by ferritin 
proteins, after nanoparticles degradation, was also proven.[132] Considering the presented data, IONPs 
can be assumed safe from a therapeutic point of view and their application for disease treatment is 
suitable for being largely extended. Of course, considerable attention has to be paid to the coating of 
the nanoparticles, and case-by-case study is needed for understanding the safeness of a IONPs-based 
formulation. 
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Figure 5.2. Biotransformation of IONPs. a) Black dashed box. Comparison of MRI scans of a non-injected 
mouse (left) and a treated mouse intratumorally injected with nanocubes (right) taken in vivo at day 6 post-
injection. A large hypointense signal, mainly localized in the tumor region denoted by a red square, is observed 
in the injected mouse. b) Light blue dashed box. Comparison of MRI scans of a control mouse and 
intravenously injected mice taken at D0, D14, D30, and D120 post-injection, showing a pronounced 
hypointense signal, mainly localized in the liver and spleen (letters L, S, and K denote the liver, spleen, and 
kidney, respectively) which is attenuating over time. c) Green dashed box. Degradation over time of nanocubes 
in lysosome-like medium. After 60 minute, the shape and morphology of the nanocrystal dramatically change 
(black dashed box and black arrows), indicating its partial degradation. The organic coating appear completely 
degraded after 60 minutes (light blue dashed line and arrows). d) Orange dashed box. TEM micrographs 
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showing a representative intracellular endosome loaded with nanocubes (left) and its magnified view (right), 
found in the spleen on the day of cube injection (D0, top). Bottom micrographs show spleen sections harvested 
4 months after injection: characteristic electron-dense lysosomes (right, and left for the magnified view) reveal 
the coexistence of scattered intact nanocubes (white arrows), a cube leftover (red arrow), and numerous 
monodisperse iron-rich ferritin proteins (blue square). (a-b) Adapted with permission from (Ref 131). Copyright (2014) 
American Chemical Society. (c-d) Adapted from Biotransformations of magnetic nanoparticles in the body, Jelena Kolosnjaj-Tabi, 
Lénaic Lartigue, Yasir Javed, Nathalie Luciani, Teresa Pellegrino, Claire Wilhelm, Damien Alloyeau, Florence Gazeau, Volume 11, 
Issue 3, June 2016, Pages 280-284,  with permission from Elsevier.  
Smart drug delivery: NPs get into action 
The need for drug nanocarriers that efficiently target diseased areas in the body arises because drug 
efficacy is often altered by nonspecific cell and tissue biodistribution, and because some drugs are 
rapidly metabolized or excreted from the body.[185] Several ways for exploiting a controlled release 
of drugs from NPs were developed so far, aiming to take advantage of the metabolic and 
environmental differences occurring between healthy and pathological tissues, or to trigger a 
synergistic response with the nanoparticles’ intrinsic features like magnetism or heating 
performance.[186] The strategies studied so far include redox release,[187] enzymatic degradation,[188] 
thermo-responsive and pH-responsive release.[189] Redox-sensitive nanosystems rely on the cleavage 
of disulphide bonds by glutathione (GSH), which is abundant in the intracellular environment (~2–
10 mM) but relatively low concentrated in the extracellular environment of healthy tissues.[185] 
Moreover, due to the high metabolic activity, some tumors express elevated glutathione concentration 
in comparison to non-diseased tissues.[190] Reducible polymers, GSH-sensitive crosslinking agents or 
thiol-cleavable bonds were used for grafting on the nanoparticles surface drugs for the treatment of 
cancer cells.[185] Enzyme-sensitive systems take advantage from the altered expression profile of 
specific enzymes (such as proteases, phospoholipases or glycosidases) observed in pathological 
conditions, such as cancer or inflammation, for triggering enzyme-mediated drug release with 
accumulation of drugs at the desired biological target. Most of the systems devoted to enzyme-
mediated drug delivery exploited the presence of enzymes in the extracellular environment, like 
matrix metalloproteinases (MMPs).[185] Thermo-responsive (TH) polymers, which can undergo 
reversible changes in physical properties in response to changes in the solution temperature, have 
become very popular. The possibility to rise the local temperature, not only of the pathological 
environment but also of the NPs coating via hyperthermia, suggested intriguing application of IONPs 
for the synergistic treatment of cancer. Indeed, while treating cancer cells by heat, it is possible to 
trigger the release of drugs from thermo-responsive polymeric shells, in which the therapeutic cargo 
is encapsulated.[191-193] This combination of treatments increases the effectiveness of the therapy, 
promoting an efficient eradication of the malignancy. Another strategy exploits the local changes in 
pH that occur naturally at different organ, tissue and cellular levels, e.g. the stomach versus the 
intestine environment, the intracellular endosomal-lysosomal compartments versus the cellular 
cytoplasm. This pH difference occurs also in some pathological conditions, such as the inflammatory 
or tumor microenvironment. pH-responsive polymers show changes in stability, solubility and 
volume in response to environmental pH changes. These features have been merged with NPs to 
produce new probes for  drug delivery systems, tracking and imaging.[185] pH-responsive polymers 
are usually synthesized by using amines or derivatives, which confer to the nanoparticles shell a 
positive charge.[185] Positively charged nanoparticles have been reported to promote the endosomal 
escape of the nanoparticles after cell uptake.[194] This phenomenon, referred as “proton sponge 
effect”[195] acquired relevance for enhancing the cytosolic release of cargo molecules, avoiding their 
degradation inside the lysosomes.[196] Despite promising results were obtained for the delivery of 
drugs and genetic materials,[197, 198] it was shown that highly positively charged nanoparticles may 
induce acute generic cytotoxicity.[199, 200] Thus, the rational design of the polymeric shell and/or the 
linkers that bound a chosen drug to the NPs surface is critical for obtaining the desired therapeutic 
effect and strictly influences the disease outcome. 
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Figure 5.3. Stimuli-responsive drug release. a) Redox-stimuli systems exploit the oxidative reduction of 
reducible linkers or polymers which bind or encapsulate drugs cargoes. b) Upon the proteolytic activity of 
enzymes specifically active at the tumor environment, therapeutic molecules are released from the enzyme-
sensitive nanosystems. c) The local decrease of pH at the tumor site or the low endosomal/lysosomal pH that 
the nanoparticles experience after the endocytosis process induce the release of the NP-bound/encapsulated 
drug following the polymer swelling. d) The local increase of temperature generated by magnetic hyperthermia 
may promote the shrinking of thermo-responsive polymer grafted on the IONPs surface. The drugs 
encapsulated inside are then release in the surrounding environment. (d) Adapted from (Ref 192) with permission of the 
Royal Society of Chemistry. 
Targeting, i.e. how to localize IONPs at the desired site 
To direct the nanoparticles towards the intended site, two different routes are usually followed: 
passive or active targeting (Figure 5.4). The first relies on the passive targeting of IONPs, based  on 
the enhanced permeation effect (EPR) typical of some tumors. The presence of irregular blood vessels 
that present a discontinuous epithelium and lack the basal membrane of normal vascular structures 
were considered for a long time as a good opportunity for the passage and accumulation of tiny IONPs 
(30-100 nm in size) at the tumor site.[201, 202] However, several concerns have been raised, recently, 
about the reliability of the EPR as general hallmark of cancer.[203, 204] Indeed, different groups reported 
that the blood vasculature architecture can greatly change from one tumor to another and that, while 
for highly permeable tumors the EPR remains an affordable factor for nanoparticles targeting, in more 
compact and dense tumor masses only small, long circulating NPs may slowly extravasate.[205] 
Therefore, linking to the IONPs surface biomolecules able to actively recognize its target may help 
to localize the therapeutic drug at the desired site. This methodology, involving an active or ligand-
mediated targeting, relies on the affinity of immobilized ligands on the nanoparticle’s surface towards 
specific molecular targets present on the tumor cells.[206]  
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Figure 5.4. Passive vs active targeting. Passive targeting exploits the EPR effect for accumulating the 
nanoparticles, with the relative therapeutic cargo, at the tumor site. The fenestrations that are present in the 
disorganized and fast growing tumor vasculature promote the extravasation of the NPs and their interaction 
with the cells of the unhealthy environment. The drug is released in the tumor ECM or intracellularly upon the 
passive uptake of the nanocarriers. Active targeting instead relies on the ligand-mediated interaction of the 
biomolecules bound to the NP surface with specific markers overexpressed or preferentially expressed on the 
cancer cells membrane. The targeting may be directed to the cells of the tumor mass or to the endothelial cells 
of the tumor vasculature. Active targeting may also take advantage of the leaky tumor vasculature and increase 
the NPs uptake at the tumor site. Adapted by permission from Macmillan Publishers Ltd: Nature Reviews Cancer (reference 9), 
copyright t (2017). 
Active targeting  
Nanoparticles have been successfully functionalized with several biological active molecules in order 
to obtain specific targeting. Small molecules, peptides and antibodies are the most frequently used 
for that purpose.[207] Small molecules or peptides allow for a high density coating on the nanoparticles 
surface, increasing the avidity for the target. Moreover, a homogeneous coating can also provide 
better stability to the nanoparticles in solution. [43, 208] Compared to small molecules or peptides, 
monoclonal antibodies (mAb) express higher specificity and affinity for their target. However, they 
are usually very expensive, poorly stable, immunogenic and difficult to handle and produce. Lately, 
small antibody fragments, differently composed of the variable heavy (VH) and light (VL) regions of 
an entire antibody and connected through natural or synthetic loop, have acquired increasing interest 
in the field of bioconjugation (Figure 5.5).[45] Among them, single-chain fragment variable 
recombinant antibodies (scFv) have shown a great potential.[45, 209, 210] Due to their small size 
(typically in the range of 20-30 kDa) they are more stable and do not present a high immunogenic 
profile.[211] Even if they express a reduced affinity for their target compared to their parent mAb, the 
binding of multiple fragments on the surface of the nanoparticles produces an increment in the avidity 
for the target, compensating the reduction of affinity.[211]  
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Figure 5.5. Antibody and antibodies fragments for NP-mediated targeting.  Monoclonal antibodies 
(mAbs) consist of four protein chains; two identical ca. 25 kDa light chains (i.e. L-subscript) and two identical 
ca. 50 kDa heavy (i.e. H-subscript) chains. These chains contain multiple domains which are characterised by 
their degree of sequence variability. The N-termini of the chains constitute the variable domain (V), which 
form the antigen-binding region. Further from the terminus, the structure becomes more conserved and is 
called constant region (C). The heavy and light chains are held together by several inter-chain disulfide bonds 
(ds) to form a Y-shaped structure. The overall structure can be divided into two distinct segments; the fragment 
antigen-binding (Fab) region and the fragment crystallisable (Fc) section. Fabs can be further divided into 
variable (Fv, VH/L) and constant (CH/L) regions.
[45] Fab, Fab’, F(ab’)2, were isolated and used alone or in 
combination with nanoparticles. Additionally, other classes of antibody fragments emerged as targeting 
molecules for NPs, such as the ScFv (green dashed box), ds-Fv, ds-ccFv, single domain antibodies (sdAb), 
and diabodies. Adapted from (Ref 45) with permission of the Royal Society of Chemistry. 
An astonishing amount of binding chemistries are available for the functionalization of the 
nanoparticles surface,[212] either exploiting the natural affinity of the chemical groups of the 
nanoparticle surface and biomolecule or relying on the modification of one or both components. [212] 
Parameters such as the ratio of biomolecule per NP, the orientation of the biomolecules onto the 
nanoparticle, as well as its distance form NP surface, control over the attachment affinity and finally, 
yet importantly, the cheapness and replicability of the chosen strategy have to be strictly considered 
(Figure 5.6). Instinctively, one can think that higher is the number of molecules bound on the NP 
surface, better would be the recognition of their target and consequently more efficient and specific 
the treatment. However, despite the possibility to exploit the high surface to volume ratio of the 
particles with the grafting of small molecules at high density, the impact of the steric hindrance of the 
biomolecules and their reciprocal interactions onto the NP surface should not be underestimated, 
especially for big biomolecules. Indeed, Colombo et al. reported that increasing the number of 
antibodies bound on the surface of gold nanoparticles reduced their effective specificity towards the 
desired cells. Their work showed that the binding of one antibody resulted in an efficient recognition 
of the target, while the nanoparticles functionalized with two antibodies were inefficient.[213] 
Intuitively, also the orientation of the biomolecules plays a crucial role for an efficient bioconjugation 
strategy. The activity of proteins, enzymes, antibodies but also small molecules like folic acid or 
biotin depends on the availability/accessibility of their active site to interact with the target molecule. 
A rational plan of the distance and orientation parameters of the biomolecules grafted on the NP 
surface is essential to ensure a precise bioconjugation construct. Indeed, non-specific chemistry or 
electrostatic interactions can result in heterogeneous attachment and impair the activity of the final 
conjugate.[212]  
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Figure 5.6. Rational binding of the biomolecules to the NP surface. Taking into consideration a toolset of 
parameters would allow controlling the attachment of any protein or biomolecule to any NP. These criteria 
include 1) control over attachment affinity; 2) control over relative separation distance from the NP; 3) control 
over the orientation and exposition of the active site on the NP; 4) control over the valence of biomolecule per 
NP. A further parameter that should be considered is the replicability of the binding strategy, i.e. the possibility 
to extend it to other biomolecules. Moreover, the intrinsic cost of the procedure chosen may facilitate the 
clinical/market translation of the nanosystems developed. Adapted with permission from (Ref 211). Copyright (2013) 
American Chemical Society. 
In addition, the stability of the bioconjugate should be assessed for its final utility. A permanent 
linkage would be preferable for providing long-term stability to the nanoconjugate, while a reversible 
binding could be more desirable in case of NP-mediated drug delivery.[212] The later can be the case 
of antibodies labeled with radionuclides used for both targeting and for killing cancer cells. pH-
cleavable or matrix metalloproteinase (MMPs)-cleavable linkers can be used for spreading the 
nanoconjugate activity at the tumor site, once that the active drug or compound is released from the 
nanocarrier.[214] When designing an active targeting strategy for cancer therapy, the protein corona 
formation around the nanoparticles must be carefully considered. Indeed, the opsonization of plasma 
proteins on the NP surface can mask the active site of the immobilized protein, thus preventing the 
interaction with its target. As presented by Salvati et al., silica NPs conjugated with transferrin lost 
their ability to recognize transferrin receptor on cells in presence of high concentration of serum 
proteins.[215] This work spreads serious criticism on the thousands of published papers that carried out 
targeting studies at serum protein concentration of 10% (amount usually used for cell culture), which 
compared to pure plasma does not resemble the in vivo conditions. This result questions the relevance 
of the in vitro tests for NP-ligand/receptor recognition.[215] Furthermore, some doubts were raised on 
the real efficiency of an active targeting strategy compared to the non-active one. Indeed, designing 
a ligand-mediated targeting strategy can be onerous in terms of cost and time, but if it does not lead 
to an improved outcome in patients it may remain interesting only scientifically and not clinically.[6] 
Noteworthy, in animal models, it was observed that the tumor accumulation for a wide range of 
nanomaterials with targeting was modest compared to nanoparticles without targeting and not always 
higher.[216] However, the presence of targeting molecules can facilitate the uptake of the nanoparticles 
and promote their internalization through specific pathways,[217] like caveolin-mediated endocytosis, 
that facilitate the activity of a cargo drug avoiding its degradation inside the lysosomes.[184] In 
conclusion, due to the many challenges and factors that influence the efficiency of a ligand-mediated 
targeting strategy, the development of a suitable nanoplatform has to be carefully planned and 
evaluated for all the single aspects composing it: 1) size and shape of the magnetic support; 2) coating 
material and charge; 3) size and composition of attached biomolecules ; 4) carrier target specificity 
and escape to clearance. 
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6. How far we are? 
… 
To better understand the potentiality of nanomedicine and fix the milestones for future research, is 
opportune to ask ourselves “How far can we go?”. Several questions were moved to the nanomedicine 
in the early 2000’s.[218] Most of these questions still have to receive suitable answers. Nanoscientists 
have to face that even if great improvements were made in the direction of a more clear 
comprehension of the behavior of nanoparticles in biological environment, still major challenges 
remain. Bioavailability, accumulation at the desired site and efficient release of the therapeutic cargo 
are just a small part of the tasks that a nanodrug has to accomplish inside the biostructures of a 
complex organism, like a human being. Poor understanding of the biological barriers, 
misinterpretation of drug delivery concepts, cost-effectiveness, manufacturing and scaling up, and 
regulatory issues, have also affected the clinical translation of nanomedicines.[219] Another major 
limitation is related to the investigation approaches hitherto used. Although cell culture studies and 
small animal models continue to be essential for the investigation of fundamental bio-nano 
interactions, it remains challenging to use these types of models to predict clinical performances.[6] 
In vitro experimentation, the use of 2D culture, which has proven to be a valuable method for cell-
based studies and basic molecular interactions, presents intrinsic limitations. Indeed, this model does 
not adequately take into account the natural 3D environment of cells in vivo, in which they are 
surrounded by other cells and extracellular matrix[220, 221] Currently, in drug discovery, the standard 
procedure for screening compounds starts with the 2D cell culture-based tests, followed by animal 
experimentation. The most commonly used model for these studies is the mouse, often 
immunodeficient, which may poorly represent the behavior of a human body.[6] Three main issues 
can be pointed out from the use of these mice: 1) the impossibility to assess the role played by the 
immune system in cancer and how its interaction with nanomedicine does affect the therapy;[219] 2) 
the enhanced permeability and retention (EPR) effect which is not accurate for such models; 3) the 
different size of the xenograft tumors implanted in mice compared to a human tumor. The relative 
size of a tumor (2 – 10 g) in a patient (70 kg) is in the range of 0.003 – 0.01%. Unlikely, the relative 
mass of a tumor (0.1 - 4 g) xenografted into and growing in a nude mouse (15 – 30 g) is in the range 
of 0.3 – 30%.[6] A tumor of this size in a mouse would correspond to the size of a basketball in a 
human.[6] As consequence, one soon realizes that it is rather easier for nanoparticles to encounter the 
tumor in mouse model, while in human this cannot be easily assumed. Thus, the differences between 
human and current animal models (tumor microenvironment, dosing regimens, bioavailability, 
pharmacokinetics, pharmacodynamics, as well as a lack of standardization in the conducting and 
reporting of preclinical studies) may originate discrepancy between what is expected from preclinical 
mouse results and what is actually observed in clinics. So far, it seems that cancer nanomedicine has 
dramatically focused on treatment of mice rather than humans. Indeed, the EPR-driven xenograft 
tumor models are ideal for demonstrating enhanced therapeutic efficacy of nanomedicine 
formulations compared to free drug but are useless from a translational point of view.[219] However, 
having cleared the complexities and challenges that are emerging with nanomedicine, several 
advances in the development of new in vitro and in vivo assays are being proposed (Figure 6.1). For 
example in vitro, 3D tumor models and spheroids,[220-222] microfluidic-based assays[223] and culturing 
of tumor explants and organoids ex vivo[224, 225] are being pursued and have shown promising results.[6] 
Considering in vivo alternatives, it is possible to count the use of immunocompetent animal models 
in which tumors develop spontaneously and comparative oncology, which examines both cancer risk 
and tumor development across species. However, thinking of being “on the right way” could turn out 
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to be a simplistic illusion. Instead, it is reasonable to imagine that what is until now firmly established 
will have to be revised in the future. Nanoscientists have the duty to lead the nanomedicine to the 
development of better devices, drugs and technologies for early diagnosis or treatment of a wide range 
of diseases with high specificity, efficacy and personalization, thus overcoming the nowadays 
limitations for a precise theranostic approach (combination of diagnosis and therapy).[3, 226]. It is 
possible that “magic bullet” concept is definitively outdate.[227] Identify the weakness of NPs is the 
best way to find what will.  
 
Figure 6.1. Overview of the approaches for developing nanomaterials for cancer treatment. The “in vitro–in vivo 
gap” is that in vitro results cannot be easily translated to in vivo settings. The “translational gap” is that strategies 
developed with the help of animal models can be difficultly translated to human patients. New approaches are emerging, 
which can help to overcome these challenges, for example 3D cell cultures and comparative oncology.[6] Reprinted with 
permission from Mattias Björnmalm, Kristofer J. Thurecht, Michael Michael, Andrew M. Scott, and Frank Caruso, Bridging Bio-Nano 
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